This post is about a clinical trial, but I post it here before it will yield the answer to the new MS model.
Some time ago, MS was considered an autoimmune disease of T-cells. These cells were present in lesions (CD4+ and CD8+) and researchers were putting the blame on them, trying to deplete them to control the disease.
Since anti-CD20 depletion success (Rituxan) scientist now know that B-cells are involved, and in fact, CD8+ T-cells are supposed to be fighting the EBV-infected B-cells. Therefore something to boost.
The new idea of intervention is to inject patients with CD8+ cytotoxic T-cells to kill EBV-infected B-cells. Something similar to Rituxan but without secondary effects.
The clinical trial is still not recruiting, but is worth to follow its course:
Trial to Assess the Safety and Feasibility of Adoptive Cell Therapy With Autologous EBV-specific Cytotoxic T Lymphocytes (CTL) in Patients With a First Clinical Episode Highly Suggestive of Multiple Sclerosis (MS and EBV-CTL)https://clinicaltrials.gov/ct2/show/NCT ... lls&rank=2